Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter

American Journal of Hospice and Palliative Medicine

Volumn 19, Issue 1, 2002, Pages 35-38

  Iyengar, Tara D ^a   Herzog, Thomas J ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

advanced cancer; cancer patients; continuous infusion; continuous intravenous morphine; morphine sulfate; opioid; pain control; palliative medicine; symptom management

Indexed keywords

AGED; ARTICLE; ASCITES; CASE REPORT; CATHETERIZATION; CYSTADENOCARCINOMA; FEMALE; HUMAN; INSTRUMENTATION; METHODOLOGY; MIDDLE AGED; MIXED MULLERIAN TUMOR; OVARY TUMOR; PALLIATIVE THERAPY;

AGED; AGED, 80 AND OVER; ASCITES; CATHETERIZATION; CYSTADENOCARCINOMA, PAPILLARY; FEMALE; HUMANS; MIDDLE AGED; MIXED TUMOR, MULLERIAN; OVARIAN NEOPLASMS; PALLIATIVE CARE;

EID: 0036359526     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910201900108     Document Type: Article

References (22)

1. Hirte HW, Miller D, Tonkin K, et al.: Randomized trial of paracentesis after intraperitoneal TNF alfpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecologic Oncology. 1997; 64(1): 80–87.
2. Lorusso V, Catino A, Gargano G, et al.: Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. European J Gynecologic Oncology. 1994; 15(1): 75–80.
3. Ward B, Mather S, Shepherd J: The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. British J Cancer. 1988; 58(5): 658–662.
4. Ariel IM, Oropeza R, Pack GT: Intracavitary administration of radioactive isotopes in the control of effusions due to cancer: Results in 267 patients. Cancer. 1966; 19: 1096–1102.
5. Paladine W, Cunningham TS, Sponzo R, et al.: Intracavitary bleomycin in the management of malignant effusions. Cancer. 1976; 38(5): 1903–1908.
6. Kefford RF, Woods RL, Fox RM, Taterall HH: Intracavitary adriamycin nitrogen mustard and tetracycline in the control of malignant effusions: A randomized study. Med J Aust. 1980; 2(8): 447–448.
7. Jackson GL, Blosser NM: Intracavitary chromic phosphate (32P) colloidal suspension therapy. Cancer. 1981; 48: 2596–2598.
8. Ozols RF, Young RC, Speyer JL, et al.: Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982; 42(10): 4265–4269.
9. Currie JL, Gall S, Weed JCJ, et al.: Intracavitary Corynebacterioum parvum for treatment of malignant effusions. Gynecol Oncol. 1983; 16:6–14.
10. Bitran JD: Intraperitoneal bleomycin: Pharmacokinetics and results of a phase II trial. Cancer. 1985; 56(10): 2420–2423.
11. Stewart JS, Hird V, Snook D, et al.: Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: Pharmacokinetics and normal tissue dosimetry. Int J Cancer. 1988; 3: 71–76.
12. Kamada M, Sakamoto Y, Funimoto H, et al.: Treatment of malignant ascites with allogeneic and autologous lymphokine-activated killer cells. Gynecol Oncol. 1989; 34(1): 34–37.
13. Bezwoda WR, Seymour L, Dansey R: Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. Cancer. 1989; 64(5): 1029–1033.
14. Cherchi PL, Campiglio A, Rubathu A, et al.: Endocavitary beta-interferon in neoplastic effusions. European J Gynecol Oncol. 1990; 11(6): 477–479.
15. Clarke-Pearson DL, Rodriguez GC, Boente M: Palliative surgery for epithelial ovarian cancer. In Rubin SC, Sutton GP (eds.): Ovarian Cancer. New York: McGraw-Hill, 1993.
16. Lund RH, Moritz MW: Complication of Denver peritoneovenous shunting. Arch Surg. 1982; 117: 924–928.
17. Campioni N, Pasquali Lasagni R, Vitucci C, et al.: Peritoneovenous shunt and neoplastic ascites: A five-year experience report. J Surgical Oncology. 1986; 33: 31–35.
18. Roussel JG, Droon, BBR, Hart GAM: The Denver type for peritoneovenous shunting of malignant ascites. Surgery, Gynecology & Obstetrics. 1986; 162: 235–240.
19. Lorentzen T, Sengelov L, Nolsoe CP, et al.: Ultrasonically guided insertion of a peritoneogastric shunt in patients with malignant ascites. ACTA Radiologica. 1995; 36(5): 481–484.
20. Belfort MA, Stevens PJ, DeHaek K, et al.: A new approach to the management of malignant ascites. European J Surgical Oncology. 1990; 16(1): 47–53.
21. Putnam JB, Ponn R, Olak J, et al.: A phase III trial of treatment for malignant pleural effusions: Pleurx pleural catheter (PC) versus chest tube and doxycycline sclerosis (CT-S). Chest. 1997; 112: 26S.
22. Richard HM, Coldwell DM, Boyd-Kranis RI, et al.: Pleurx tunneled catheter in the management of malignant ascites. J Vasc Interv Radiol. 2001; 12: 373–375.